Biological Specimen Raw Material Sourcing for IVD Development: Human Serum, Plasma, and Matrix Materials

How to source biological specimen raw materials — human serum, plasma, urine, CSF, and tissue-derived matrices — for IVD calibrator and control manufacturing, including donor qualification, viral testing, traceability, TSE/BSE compliance, lot-to-lot consistency, and regulatory requirements under FDA 21 CFR 610, EU IVDR, and ISO 13485.

Why Biological Raw Material Sourcing Is the Hidden Bottleneck in IVD Manufacturing

Every IVD kit contains a critical biological component that determines whether the assay's results are trustworthy: the matrix material used to prepare calibrators and controls. That matrix — human serum, source plasma, defibrinated plasma, disease-state material, or a synthetic alternative — must mimic patient samples closely enough that the assay's analytical performance can be verified on every lot. If the matrix is inconsistent, contaminated, unavailable, or incorrectly characterized, the entire assay's quality claim collapses.

Unlike synthetic reagents and chemical buffers, biological specimens are inherently variable. They come from human donors whose analyte levels, antibody profiles, and lipid compositions differ from person to person and from collection to collection. They are regulated as biological products when sourced from blood establishments, which means donor screening, viral testing, traceability, and manufacturing controls must comply with 21 CFR Part 610, EU blood directives, and the IVDR's requirements for materials of human origin. And they are perishable — stored frozen, sensitive to freeze-thaw, and subject to lot expiration constraints that do not apply to lyophilized antibodies or synthetic oligonucleotides.

For IVD manufacturers, the challenge is not just finding a supplier. It is building a sourcing strategy that ensures continuous supply, lot-to-lot consistency, regulatory defensibility, and cost control — often for dozens of different analyte-specific matrices across a product line. This article addresses the full lifecycle of biological specimen raw material sourcing, from donor qualification and safety testing through supplier evaluation, lot acceptance, change control, and the emerging alternatives that reduce dependence on human-derived materials.

The Biological Raw Material Universe for IVD

Human Serum

Serum is the liquid fraction of coagulated blood — plasma without fibrinogen and clotting factors. It is the most commonly used matrix for clinical chemistry calibrators and immunoassay controls because its composition closely matches that of patient samples processed in routine laboratory testing.

Normal human serum, often pooled from healthy donors, serves as a base matrix for calibrators where the analyte of interest is spiked to defined concentrations. Disease-state serum, collected from donors with confirmed clinical conditions (elevated cardiac markers, autoimmune antibodies, infectious disease antibodies), is used for positive controls and trueness verification.

Key sourcing considerations for serum include:

Donor pool size: Larger pools dilute individual donor variability and produce more consistent lots. Suppliers like Grifols Bio Supplies leverage their network of over 300 plasma collection centers across the U.S. to produce large lot sizes, which improves lot-to-lot reproducibility.
Anticoagulant carryover: Serum, by definition, should contain no anticoagulant. However, if serum is prepared from collected whole blood, the clotting process must be complete and well-controlled. Incomplete clotting can leave residual fibrinogen that causes interference in downstream assays.
Analyte depletion: For calibrator matrices, specific analytes (cholesterol, glucose, hormones) may need to be removed or depleted to create a "blank" matrix into which known concentrations can be spiked. Techniques include charcoal stripping, immunodepletion, and selective filtration. Each depletion method introduces its own risk of co-removing unrelated analytes or altering the matrix's protein composition.

Source Plasma and Processed Plasma

Source plasma is collected through plasmapheresis, where blood is drawn, the plasma is separated by centrifugation, and the cellular components are returned to the donor. This allows larger volumes per donation and more frequent donations compared to whole blood collection.

Plasma is preferred over serum in some contexts because:

Collection is more efficient for bulk production
The defibrination process can be controlled to produce a more uniform matrix
Specific processing steps (defibrination, delipidation, analyte adjustment) can be applied to customize the final product

Grifols and other major suppliers offer processed plasma products where defibrination removes fibrinogen and clotting factors, creating a stable, clot-free matrix that performs more consistently in calibrator and control formulations. Defibrinated plasma is particularly useful because it avoids the variability introduced by uncontrolled clotting in serum preparation.

Disease-State Materials

For infectious disease IVDs, autoimmune panels, and tumor marker assays, the calibrator or control must contain the actual target analyte at clinically relevant concentrations. This means sourcing serum or plasma from donors who are confirmed positive for the condition — HIV antibodies, hepatitis B surface antigen, elevated troponin, rheumatoid factor, or tumor-associated antigens.

Disease-state sourcing is the most challenging category because:

Donor identification and consent: Donors must be identified through clinical testing, and their specimens must be collected under ethical guidelines with appropriate informed consent. SERION Immunologics, for example, collects disease-state sera at approved blood centers in the U.S. and Europe with full donor traceability.
Titer variability: A single donor's antibody titer may not be reproducible across collections. Bulk pooling of multiple positive donors helps average out this variability, but availability of donors with high enough titers is a recurring constraint.
Regulatory restrictions: Certain disease-state materials (HIV-positive plasma, hepatitis-positive serum) are subject to additional shipping, handling, and biosafety requirements that complicate international sourcing.

Urine, CSF, and Other Body Fluids

Some IVD assays target analytes measured in matrices other than blood. Urine-based assays (hCG, drugs of abuse, albumin-to-creatinine ratio) require human urine pools. CSF-based assays (neurological biomarkers, meningitis panels) require cerebrospinal fluid. Saliva, sweat, and stool specimens are relevant for specific point-of-care and molecular diagnostic platforms.

These non-blood matrices are typically harder to source in bulk because collection is less standardized, donor pools are smaller, and the volume per donation is more limited. Sourcing strategies for these materials often involve specialized biospecimen banks and clinical collection networks rather than large-scale plasma collection centers.

Animal-Derived Materials

Bovine serum albumin (BSA), fetal bovine serum (FBS), and other animal-derived proteins are used as blocking agents, stabilizers, and diluent components in IVD reagent formulations. While not specimen matrices per se, they are biological raw materials subject to their own sourcing and safety requirements:

TSE/BSE compliance: EU Regulation 1069/2009/EC classifies animal by-products into three risk categories. Materials used in IVD manufacturing must be sourced from Category 3 (lowest risk) materials, with documented country-of-origin traceability and processing records. MedTech Europe and ISIA have published guidance on compliance with animal by-product regulations for medical devices.
Supplier certification: BSA and FBS suppliers must provide certificates of origin, TSE/BSE declarations, and viral safety documentation. ISO 13485 requires that these materials be treated as critical raw materials when they directly affect assay performance.

Donor Qualification and Viral Safety

Regulatory Framework

In the United States, donor eligibility and viral testing for blood and plasma products are governed by 21 CFR Part 610 and 21 CFR Part 1271 Subpart C. The FDA requires that all donors of human cells, tissues, and cellular and tissue-based products (HCT/Ps) be screened for relevant communicable disease agents or diseases (RCDADs) and that a donor eligibility determination be made prior to product distribution.

For IVD raw material sourcing, the key requirement is that the biological material comes from donors who have been tested and found non-reactive for:

HIV-1 and HIV-2 (antibody/antigen and NAT)
Hepatitis B virus (HBsAg and HBV NAT)
Hepatitis C virus (anti-HCV and HCV NAT)
Human T-cell lymphotropic virus (HTLV-I/II)
Syphilis

In the EU, the Blood Directives (2002/98/EC, 2004/33/EC, 2005/61/EC, 2005/62/EC) establish equivalent requirements for donor eligibility, testing, and traceability. Additionally, EU IVDR 2017/746 Annex I requires that IVD devices manufactured using materials of human origin comply with the relevant Community legislation on the quality and safety of these materials.

NAT Testing and Pathogen Reduction

Nucleic acid amplification testing (NAT) has become the standard for screening donor plasma and serum. NAT detects viral genetic material during the window period before antibodies are produced, significantly reducing the risk of transmitting infections through biological products.

Major suppliers perform the following NAT tests on donor material:

Test	US Requirement	EU Requirement
HIV-1/2 NAT	Required	Required
HCV NAT	Required	Required
HBV NAT	Required	Required
HAV NAT	Required	Required
HEV NAT	Not routinely required	Required
Parvovirus B19 NAT	Required	Required

Grifols Bio Supplies, for example, performs all of these tests at its FDA-licensed and EMA-licensed collection centers, with donor traceability maintained throughout the supply chain.

Pathogen reduction and inactivation methods provide an additional safety layer for biological raw materials used in IVD manufacturing. Solvent/detergent (S/D) treatment inactivates lipid-enveloped viruses (HIV, HCV, HBV). Heat treatment and nanofiltration address non-enveloped viruses. However, these methods can alter the protein composition of the matrix and must be validated for their impact on assay performance.

Traceability Requirements

ISO 13485:2016 Clause 7.5.9 requires traceability for implantable medical devices and for components and materials used in situations where traceability is a specified requirement. For IVD manufacturers, biological raw materials fall squarely within this scope because they directly affect the analytical performance of the final product.

Traceability for biological specimens must include:

Donor identification: A unique donor ID that links to the collection event, the collection center, and the donor's eligibility records.
Collection records: Date, location, collection method (plasmapheresis, whole blood draw), anticoagulant used, and any adverse events during collection.
Testing records: All viral screening results, including NAT and serology, with dates and testing laboratory identification.
Processing records: Any manipulation of the raw material (pooling, defibrination, delipidation, filtration, aliquoting) with batch records and equipment logs.
Storage and shipping records: Temperature monitoring, freeze-thaw history, chain-of-custody documentation from collection to receipt at the IVD manufacturing site.

In the EU, the IVDR requires that IVD manufacturers using materials of human origin maintain records that allow the competent authority to trace those materials from the donor to the finished device and vice versa. This bidirectional traceability is essential for post-market vigilance and recall management.

Supplier Evaluation and Qualification

Supplier Selection Criteria

Selecting a biological raw material supplier requires evaluation criteria that go beyond the typical supplier audit checklist. The supplier's regulatory posture, donor base, and manufacturing controls are equally important as their product specifications.

Critical evaluation factors include:

Regulatory licensing: Does the supplier's collection facility hold FDA licensure (for U.S.-sourced materials) or EMA licensing (for EU-sourced materials)? Suppliers operating under cGMP at FDA-licensed centers provide an additional assurance of donor qualification and viral testing compliance.
ISO 13485 certification: Does the supplier manufacture their products under an ISO 13485 quality management system? BBI Solutions, for example, manufactures depleted serum and releases externally sourced disease-state plasma under ISO 13485 at their facility in Crumlin, UK, and is licensed to store human tissue by the UK Human Tissue Authority.
Lot size and pooling strategy: Larger lots reduce the frequency of lot-to-lot bridging studies. Ask about the supplier's typical lot sizes, their pooling strategy, and whether they can reserve bulk material for future lot production.
Customization capabilities: Can the supplier perform analyte-specific adjustments (spiking, depletion, dilution) to meet your exact matrix requirements? Grifols offers customization of plasma products including defibrination, delipidation, and analyte adjustment.
Change notification commitment: Has the supplier committed to notifying you of any changes to their collection, processing, or testing procedures? This is a regulatory expectation under ISO 13485 Clause 7.1.3 and is critical for maintaining your validated raw material specifications.
Continuity of supply: What is the supplier's capacity to provide material over the projected lifecycle of your IVD product? A supplier dependent on a small number of collection centers or a limited donor pool may not be able to sustain supply for a product that runs for 10+ years.

Quality Agreement Provisions

The quality agreement with a biological raw material supplier must address specific provisions that do not typically appear in agreements for chemical or synthetic material suppliers:

Donor qualification requirements: Specify the viral testing panel, the testing methods (NAT vs. serology), and the frequency of donor re-qualification.
Lot definition and traceability: Define how the supplier identifies a lot, what records are maintained, and how traceability is ensured from donor to lot.
Specification stability: Commit the supplier to maintaining the agreed specifications over the life of the contract, with advance notification (typically 12-24 months) of any proposed changes.
Reserved inventory: For critical raw materials with long lead times, negotiate a reservation agreement where the supplier holds bulk material against your future orders.
Retention samples: Require the supplier to retain samples of each lot for a defined period to support your complaint investigation and lot failure analysis.

Incoming Inspection and Lot Acceptance

When you receive a lot of biological raw material, the incoming inspection process must verify both the documentation and the material itself:

Documentation review: Certificate of Analysis (CoA) confirming that all specified parameters (analyte concentrations, protein content, pH, osmolality, visual appearance) are within specification. Certificate of Origin (CoO) for materials of animal origin. TSE/BSE declaration. Viral testing records. Chain-of-custody documentation.
Physical inspection: Visual examination for particulates, discoloration, or container damage. Verification that cold-chain integrity was maintained during shipping (temperature logger review).
Analytical confirmation: For critical parameters, perform your own confirmatory testing. This may include protein concentration measurement, specific analyte quantification by your own assay method, and bioburden or endotoxin testing if the material will be used without further processing.
Functional evaluation: Test the new lot in your assay system to confirm that calibrator or control performance (recovery, linearity, precision) meets established criteria before releasing the lot for production use.

Lot-to-Lot Consistency and Bridging

The Root Problem

Biological specimens are inherently more variable than synthetic chemicals. Even with rigorous donor screening and controlled pooling, the composition of serum or plasma lots will vary in protein content, lipid levels, enzyme activity, and endogenous analyte concentrations. For IVD manufacturers, this means that every new lot of biological raw material must be evaluated for its impact on assay performance.

Logical Biological, a supplier of bulk serum and plasma for IVD applications, identifies three critical requirements for raw material consistency: consistent analyte values, reliable availability, and scalability without quality compromise. These requirements translate into specific lot-to-lot bridging practices:

Bridging Study Design

A lot-to-lot bridging study for biological raw materials typically involves:

Side-by-side testing: Run the outgoing lot and the incoming lot in parallel on the same assay platform, using the same reagent lot and instrument calibration. A minimum of 5 replicates per level, across at least 3 analyte concentrations (low, mid, high), is standard practice.
Statistical criteria: Apply pre-defined acceptance criteria for the difference between outgoing and incoming lot means. Common criteria include a maximum 5-10% difference for quantitative analytes and concordance for qualitative results.
Matrix interaction assessment: Evaluate whether the new lot's matrix affects the assay differently from the outgoing lot. This is particularly important for immunoassays where heterophilic antibody interference, rheumatoid factor, or complement activity can vary between serum lots.
Documentation: All bridging study results must be documented in a lot-to-lot bridging report, reviewed and approved by quality assurance, and retained as part of the device master record.

Reducing Bridging Frequency

To minimize the burden of lot-to-lot bridging:

Negotiate larger lot sizes with your supplier. A single lot that lasts 12-18 months is far more manageable than quarterly lot changes.
Qualify multiple lots simultaneously by purchasing and releasing two or three lots at the time of initial qualification, creating a buffer against future lot failures.
Work with suppliers who produce from the same donor pool or collection campaign, as lots from the same campaign will be more consistent than lots from different campaigns.

Emerging Alternatives: Reducing Dependence on Human-Derived Materials

Recombinant and Chimeric Antibody-Based Controls

One of the most significant developments in biological raw material sourcing is the shift toward recombinant and chimeric antibody alternatives for control and calibrator matrices. Instead of sourcing disease-state plasma from positive donors, IVD manufacturers can use engineered antibodies that mimic the target analyte.

Werfen, in partnership with ArkAb, has demonstrated this approach for immunoassay calibrators and controls. Human chimeric antibodies were developed using recombinant antigens supplied by Werfen, and the resulting chimeric-based calibrators and controls showed equivalent performance to plasma-based materials in chemiluminescence immunoassays — while reducing lot-to-lot variability and increasing supply robustness.

This approach addresses the fundamental availability problem: chimeric antibodies can be produced on demand in cell culture systems, eliminating dependence on donor availability, disease prevalence, and ethical constraints on collecting positive specimens.

Synthetic and Surrogate Matrices

For clinical chemistry applications, synthetic matrices that mimic the protein and electrolyte composition of human serum are increasingly available. These matrices typically contain purified human serum albumin, gamma globulins, and defined concentrations of key analytes in a buffered solution.

Advantages include:

Consistent lot-to-lot composition with no donor variability
No viral safety concerns and no TSE/BSE compliance requirements
Unlimited supply without dependence on donor collection

Limitations include:

Incomplete mimicry of the full protein and lipid composition of real serum, which can affect some assay formats
May not be accepted by regulators as equivalent to human-derived matrices for all applications
Cannot be used for assays that depend on endogenous analytes at clinical concentrations (disease-state materials)

Engineered Disease-State Plasma

Logical Biological and other suppliers offer "engineered" disease-state plasma, where specific analytes are spiked into normal human plasma to create defined concentrations that mimic disease conditions. This approach combines the matrix realism of human plasma with the consistency of a defined spiking process.

Engineered plasma is particularly useful when:

Natural disease-state material is unavailable (rare conditions, low prevalence)
Consistent analyte concentrations are needed across multiple lots
Multiple analytes must be present in the same control material

Cold Chain, Storage, and Stability

Handling Requirements

Human serum and plasma must be stored and shipped frozen, typically below -15°C and preferably at -20°C or colder. BBI Solutions recommends storage below -15°C with dry ice shipping to maintain cold-chain integrity. Repeated freeze-thaw cycles must be avoided because they can cause protein denaturation, fibrin formation, and analyte degradation that renders the material unsuitable for use.

For IVD manufacturers, this means:

Receiving procedures: Temperature monitoring during shipping (data loggers), immediate transfer to qualified freezers upon receipt, and documentation of any temperature excursions.
Thawing procedures: Controlled thawing at 2-8°C or in a water bath at 20-25°C, with defined maximum hold times at each temperature.
In-process storage: Once thawed and used in calibrator or control formulation, the final product's stability must be validated independently — the raw material's stability claims do not transfer to the formulated product.
Stability studies: ISO 23640:2011 provides the framework for evaluating the stability of IVD reagents, including those manufactured from biological raw materials. Real-time and accelerated stability studies must be conducted on the final formulated product, not just on the raw material.

Shelf Life and Lot Planning

Biological raw materials have finite shelf lives that are typically 2-5 years from the date of manufacture when stored frozen. For IVD manufacturers with long product lifecycles, this creates a planning challenge:

Raw material shelf life must accommodate your manufacturing cycle time, finished product stability testing duration, and the intended shelf life of the final product.
If a raw material lot expires before the finished product's shelf life ends, you may need to commit to using the material within a defined window and accept that a change to a new lot will be required during the finished product's shelf life.
Some suppliers offer extended stability data based on real-time studies, but this must be supported by documented evidence and should not be assumed without verification.

Regulatory Filing Considerations

Premarket Submissions

When you file a 510(k), PMA, or CE-IVD submission, the biological raw materials used in your calibrators and controls are part of the device description and manufacturing information that regulators will review. Key considerations:

Raw material identification: Identify the source material (human serum, source plasma, etc.), the supplier, and the critical quality attributes in your device master record.
Safety documentation: For materials of human origin, include or reference viral safety data, donor screening protocols, and pathogen reduction measures.
Change notification: If you change the biological raw material supplier or the specific raw material product after market authorization, assess whether the change requires a new submission, a supplemental filing, or can be documented through your post-market change control process.
ISO 17511 traceability: ISO 17511:2020 establishes the requirements for metrological traceability of values assigned to calibrators and control materials. Your biological raw material sourcing strategy must support the traceability chain from higher-order reference materials through your calibrators to patient results.

FDA's LDT Enforcement and Specimen Collection

The FDA's phased enforcement of IVD regulations for laboratory developed tests (LDTs), which began in 2025, has brought specimen collection devices and kits under increased scrutiny. Under 21 CFR 809.3(a), any product intended for use in the collection, preparation, and examination of specimens taken from the human body is classified as an IVD product. This means that specimen collection devices are independently regulated as medical devices, regardless of whether the LDT itself is subject to enforcement discretion.

For IVD manufacturers, this reinforces the importance of treating biological specimen collection, handling, and sourcing as regulated activities — not just procurement logistics.

EU IVDR Requirements

Under EU IVDR 2017/746, IVD manufacturers using materials of human origin must:

Ensure that materials are sourced from donors who meet the eligibility criteria established in the EU Blood Directives and the EU Tissue and Cells Directives.
Maintain records that allow bidirectional traceability from donor to finished device.
Document the viral safety measures applied to the material, including donor screening, NAT testing, and any pathogen reduction processes.
Include this information in the technical documentation that supports the CE marking of the device.

Strategic Sourcing Framework

Single Source vs. Dual Source

For most IVD manufacturers, biological raw materials are single-sourced by necessity — there are only a handful of qualified suppliers with the collection infrastructure, regulatory credentials, and product range to support commercial IVD production. However, the risks of single sourcing (supply disruption, supplier quality failure, regulatory action against the supplier) are significant.

Practical strategies for managing single-source risk include:

Safety stock: Maintain a buffer inventory equivalent to 6-12 months of production requirements, qualified and released for use.
Secondary supplier qualification: Even if you do not routinely purchase from a secondary supplier, qualify one or two alternative suppliers so that you can switch quickly if your primary supplier encounters a problem. Boyd Biomedical recommends periodic side-by-side assessment of dual-sourced materials at least once or twice per year.
Contractual protections: Negotiate supply agreements with your primary supplier that include minimum supply commitments, advance discontinuation notice (12-24 months), and provisions for technology transfer of the supplier's material specifications to your designated alternative supplier in the event of supply termination.

Lifecycle Planning

Biological raw material sourcing must be planned over the full lifecycle of the IVD product, not just for the current production period:

At design transfer: Qualify the biological raw material supplier and the specific raw material product as part of your design transfer process. Include raw material specifications, acceptance criteria, and bridging study protocols in the device master record.
During commercial production: Monitor supplier performance through incoming inspection results, lot failure rates, and on-time delivery metrics. Conduct periodic supplier audits (typically annually for critical suppliers).
At raw material change: When a change to the biological raw material is necessary (new lot, new supplier, new processing method), execute the bridging study, update the device master record, and assess whether a regulatory filing update is required.
At product end-of-life: If you are discontinuing an IVD product, coordinate with your biological raw material supplier to consume remaining inventory and wind down supply agreements without waste.

Practical Takeaways

Treat biological raw materials as critical components, not commodities. Their variability, regulatory complexity, and supply chain fragility demand the same level of control as any active reagent or critical component in your IVD.
Build your sourcing strategy around lot size maximization, advance qualification of multiple lots, and documented bridging protocols. The cost of holding inventory is far less than the cost of a production shutdown or a failed lot release.
Invest in relationships with at least two qualified suppliers, even if you only purchase from one routinely. The IVD industry's dependence on a small number of biological material suppliers makes supply continuity a strategic risk.
Evaluate recombinant and engineered alternatives for their potential to reduce your dependence on human-derived materials. The technology is maturing rapidly, and regulators are increasingly familiar with synthetic and chimeric control materials.
Document everything — donor traceability, viral testing, incoming inspection results, bridging studies, cold-chain records. Under the FDA's QMSR (effective February 2, 2026) and the EU IVDR, inspector expectations for biological raw material documentation are higher than ever.